img

Global Pulmonary Fibrosis Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Pulmonary Fibrosis Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Pulmonary fibrosis is a lung disorder characterized by damage or scarring of the lung tissue. Once the tissue is damaged, it obstructs the passageway for air and thus hinders the normal functioning of the lungs. It is usually caused as a result of certain medical conditions, exposure to toxins, pollutants or radiation or by certain medications.
Pulmonary Fibrosis Drug report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pulmonary Fibrosis Drug market is projected to reach US$ 6088.1 million in 2029, increasing from US$ 4325 million in 2022, with the CAGR of 5.0% during the period of 2024 to 2029. Demand from Hospital and Clinic are the major drivers for the industry.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pulmonary Fibrosis Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Boehringer Ingelheim
Roche
FibroGen, Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Company
MediciNova, Inc.
Genentech, Inc.
Cipla Inc.
Biogen
Galapagos NV
Segment by Type
Pirfenidone
Nintedanib

Segment by Application


Hospital
Clinic

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Pulmonary Fibrosis Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pulmonary Fibrosis Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pulmonary Fibrosis Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Pulmonary Fibrosis Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pulmonary Fibrosis Drug introduction, etc. Pulmonary Fibrosis Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Pulmonary Fibrosis Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Pulmonary Fibrosis Drug Market Overview
1.1 Pulmonary Fibrosis Drug Product Overview
1.2 Pulmonary Fibrosis Drug Market Segment by Type
1.2.1 Pirfenidone
1.2.2 Nintedanib
1.3 Global Pulmonary Fibrosis Drug Market Size by Type
1.3.1 Global Pulmonary Fibrosis Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Pulmonary Fibrosis Drug Historic Market Size Review by Type (2018-2024)
1.3.3 Global Pulmonary Fibrosis Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Pulmonary Fibrosis Drug Sales Breakdown by Type (2018-2024)
1.4.2 Europe Pulmonary Fibrosis Drug Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Pulmonary Fibrosis Drug Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Pulmonary Fibrosis Drug Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Pulmonary Fibrosis Drug Sales Breakdown by Type (2018-2024)
2 Global Pulmonary Fibrosis Drug Market Competition by Company
2.1 Global Top Players by Pulmonary Fibrosis Drug Sales (2018-2024)
2.2 Global Top Players by Pulmonary Fibrosis Drug Revenue (2018-2024)
2.3 Global Top Players by Pulmonary Fibrosis Drug Price (2018-2024)
2.4 Global Top Manufacturers Pulmonary Fibrosis Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Pulmonary Fibrosis Drug Market Competitive Situation and Trends
2.5.1 Pulmonary Fibrosis Drug Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Pulmonary Fibrosis Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pulmonary Fibrosis Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Pulmonary Fibrosis Drug Market
2.8 Key Manufacturers Pulmonary Fibrosis Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Pulmonary Fibrosis Drug Status and Outlook by Region
3.1 Global Pulmonary Fibrosis Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Pulmonary Fibrosis Drug Historic Market Size by Region
3.2.1 Global Pulmonary Fibrosis Drug Sales in Volume by Region (2018-2024)
3.2.2 Global Pulmonary Fibrosis Drug Sales in Value by Region (2018-2024)
3.2.3 Global Pulmonary Fibrosis Drug Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Pulmonary Fibrosis Drug Forecasted Market Size by Region
3.3.1 Global Pulmonary Fibrosis Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Pulmonary Fibrosis Drug Sales in Value by Region (2024-2029)
3.3.3 Global Pulmonary Fibrosis Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Pulmonary Fibrosis Drug by Application
4.1 Pulmonary Fibrosis Drug Market Segment by Application
4.1.1 Hospital
4.1.2 Clinic
4.2 Global Pulmonary Fibrosis Drug Market Size by Application
4.2.1 Global Pulmonary Fibrosis Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Pulmonary Fibrosis Drug Historic Market Size Review by Application (2018-2024)
4.2.3 Global Pulmonary Fibrosis Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Pulmonary Fibrosis Drug Sales Breakdown by Application (2018-2024)
4.3.2 Europe Pulmonary Fibrosis Drug Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Pulmonary Fibrosis Drug Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Pulmonary Fibrosis Drug Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Pulmonary Fibrosis Drug Sales Breakdown by Application (2018-2024)
5 North America Pulmonary Fibrosis Drug by Country
5.1 North America Pulmonary Fibrosis Drug Historic Market Size by Country
5.1.1 North America Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Pulmonary Fibrosis Drug Sales in Volume by Country (2018-2024)
5.1.3 North America Pulmonary Fibrosis Drug Sales in Value by Country (2018-2024)
5.2 North America Pulmonary Fibrosis Drug Forecasted Market Size by Country
5.2.1 North America Pulmonary Fibrosis Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Pulmonary Fibrosis Drug Sales in Value by Country (2024-2029)
6 Europe Pulmonary Fibrosis Drug by Country
6.1 Europe Pulmonary Fibrosis Drug Historic Market Size by Country
6.1.1 Europe Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Pulmonary Fibrosis Drug Sales in Volume by Country (2018-2024)
6.1.3 Europe Pulmonary Fibrosis Drug Sales in Value by Country (2018-2024)
6.2 Europe Pulmonary Fibrosis Drug Forecasted Market Size by Country
6.2.1 Europe Pulmonary Fibrosis Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Pulmonary Fibrosis Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Pulmonary Fibrosis Drug by Region
7.1 Asia-Pacific Pulmonary Fibrosis Drug Historic Market Size by Region
7.1.1 Asia-Pacific Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Pulmonary Fibrosis Drug Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Pulmonary Fibrosis Drug Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Pulmonary Fibrosis Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Pulmonary Fibrosis Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Pulmonary Fibrosis Drug Sales in Value by Region (2024-2029)
8 Latin America Pulmonary Fibrosis Drug by Country
8.1 Latin America Pulmonary Fibrosis Drug Historic Market Size by Country
8.1.1 Latin America Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Pulmonary Fibrosis Drug Sales in Volume by Country (2018-2024)
8.1.3 Latin America Pulmonary Fibrosis Drug Sales in Value by Country (2018-2024)
8.2 Latin America Pulmonary Fibrosis Drug Forecasted Market Size by Country
8.2.1 Latin America Pulmonary Fibrosis Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Pulmonary Fibrosis Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Pulmonary Fibrosis Drug by Country
9.1 Middle East and Africa Pulmonary Fibrosis Drug Historic Market Size by Country
9.1.1 Middle East and Africa Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Pulmonary Fibrosis Drug Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Pulmonary Fibrosis Drug Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Pulmonary Fibrosis Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Pulmonary Fibrosis Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Pulmonary Fibrosis Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Boehringer Ingelheim
10.1.1 Boehringer Ingelheim Company Information
10.1.2 Boehringer Ingelheim Introduction and Business Overview
10.1.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Boehringer Ingelheim Pulmonary Fibrosis Drug Products Offered
10.1.5 Boehringer Ingelheim Recent Development
10.2 Roche
10.2.1 Roche Company Information
10.2.2 Roche Introduction and Business Overview
10.2.3 Roche Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Roche Pulmonary Fibrosis Drug Products Offered
10.2.5 Roche Recent Development
10.3 FibroGen, Inc.
10.3.1 FibroGen, Inc. Company Information
10.3.2 FibroGen, Inc. Introduction and Business Overview
10.3.3 FibroGen, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.3.4 FibroGen, Inc. Pulmonary Fibrosis Drug Products Offered
10.3.5 FibroGen, Inc. Recent Development
10.4 Merck & Co., Inc.
10.4.1 Merck & Co., Inc. Company Information
10.4.2 Merck & Co., Inc. Introduction and Business Overview
10.4.3 Merck & Co., Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Merck & Co., Inc. Pulmonary Fibrosis Drug Products Offered
10.4.5 Merck & Co., Inc. Recent Development
10.5 Bristol-Myers Squibb Company
10.5.1 Bristol-Myers Squibb Company Company Information
10.5.2 Bristol-Myers Squibb Company Introduction and Business Overview
10.5.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Products Offered
10.5.5 Bristol-Myers Squibb Company Recent Development
10.6 MediciNova, Inc.
10.6.1 MediciNova, Inc. Company Information
10.6.2 MediciNova, Inc. Introduction and Business Overview
10.6.3 MediciNova, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.6.4 MediciNova, Inc. Pulmonary Fibrosis Drug Products Offered
10.6.5 MediciNova, Inc. Recent Development
10.7 Genentech, Inc.
10.7.1 Genentech, Inc. Company Information
10.7.2 Genentech, Inc. Introduction and Business Overview
10.7.3 Genentech, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Genentech, Inc. Pulmonary Fibrosis Drug Products Offered
10.7.5 Genentech, Inc. Recent Development
10.8 Cipla Inc.
10.8.1 Cipla Inc. Company Information
10.8.2 Cipla Inc. Introduction and Business Overview
10.8.3 Cipla Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Cipla Inc. Pulmonary Fibrosis Drug Products Offered
10.8.5 Cipla Inc. Recent Development
10.9 Biogen
10.9.1 Biogen Company Information
10.9.2 Biogen Introduction and Business Overview
10.9.3 Biogen Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Biogen Pulmonary Fibrosis Drug Products Offered
10.9.5 Biogen Recent Development
10.10 Galapagos NV
10.10.1 Galapagos NV Company Information
10.10.2 Galapagos NV Introduction and Business Overview
10.10.3 Galapagos NV Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Galapagos NV Pulmonary Fibrosis Drug Products Offered
10.10.5 Galapagos NV Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Pulmonary Fibrosis Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Pulmonary Fibrosis Drug Industrial Chain Analysis
11.4 Pulmonary Fibrosis Drug Market Dynamics
11.4.1 Pulmonary Fibrosis Drug Industry Trends
11.4.2 Pulmonary Fibrosis Drug Market Drivers
11.4.3 Pulmonary Fibrosis Drug Market Challenges
11.4.4 Pulmonary Fibrosis Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Pulmonary Fibrosis Drug Distributors
12.3 Pulmonary Fibrosis Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Pirfenidone
Table 2. Major Company of Nintedanib
Table 3. Global Pulmonary Fibrosis Drug Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 4. Global Pulmonary Fibrosis Drug Sales by Type (2018-2024) & (K Units)
Table 5. Global Pulmonary Fibrosis Drug Sales Market Share in Volume by Type (2018-2024)
Table 6. Global Pulmonary Fibrosis Drug Sales by Type (2018-2024) & (US& Million)
Table 7. Global Pulmonary Fibrosis Drug Market Share in Value by Type (2018-2024)
Table 8. Global Pulmonary Fibrosis Drug Price by Type (2018-2024) & (US$/Unit)
Table 9. Global Pulmonary Fibrosis Drug Sales by Type (2024-2029) & (K Units)
Table 10. Global Pulmonary Fibrosis Drug Sales Market Share in Volume by Type (2024-2029)
Table 11. Global Pulmonary Fibrosis Drug Sales by Type (2024-2029) & (US$ Million)
Table 12. Global Pulmonary Fibrosis Drug Sales Market Share in Value by Type (2024-2029)
Table 13. Global Pulmonary Fibrosis Drug Price by Type (2024-2029) & (US$/Unit)
Table 14. North America Pulmonary Fibrosis Drug Sales by Type (2018-2024) & (K Units)
Table 15. North America Pulmonary Fibrosis Drug Sales by Type (2018-2024) & (US$ Million)
Table 16. Europe Pulmonary Fibrosis Drug Sales (K Units) by Type (2018-2024)
Table 17. Europe Pulmonary Fibrosis Drug Sales by Type (2018-2024) & (US$ Million)
Table 18. Asia-Pacific Pulmonary Fibrosis Drug Sales (K Units) by Type (2018-2024)
Table 19. Asia-Pacific Pulmonary Fibrosis Drug Sales by Type (2018-2024) & (US$ Million)
Table 20. Latin America Pulmonary Fibrosis Drug Sales (K Units) by Type (2018-2024)
Table 21. Latin America Pulmonary Fibrosis Drug Sales by Type (2018-2024) & (US$ Million)
Table 22. Middle East and Africa Pulmonary Fibrosis Drug Sales (K Units) by Type (2018-2024)
Table 23. Middle East and Africa Pulmonary Fibrosis Drug Sales by Type (2018-2024) & (US$ Million)
Table 24. Global Pulmonary Fibrosis Drug Sales by Company (2018-2024) & (K Units)
Table 25. Global Pulmonary Fibrosis Drug Sales Share by Company (2018-2024)
Table 26. Global Pulmonary Fibrosis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 27. Global Pulmonary Fibrosis Drug Revenue Share by Company (2018-2024)
Table 28. Global Market Pulmonary Fibrosis Drug Price by Company (2018-2024) & (US$/Unit)
Table 29. Global Pulmonary Fibrosis Drug Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 30. Global Pulmonary Fibrosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 31. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pulmonary Fibrosis Drug as of 2022)
Table 32. Date of Key Manufacturers Enter into Pulmonary Fibrosis Drug Market
Table 33. Key Manufacturers Pulmonary Fibrosis Drug Product Type
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global Pulmonary Fibrosis Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 36. Global Pulmonary Fibrosis Drug Sales by Region (2018-2024) & (K Units)
Table 37. Global Pulmonary Fibrosis Drug Sales Market Share in Volume by Region (2018-2024)
Table 38. Global Pulmonary Fibrosis Drug Sales by Region (2018-2024) & (US$ Million)
Table 39. Global Pulmonary Fibrosis Drug Sales Market Share in Value by Region (2018-2024)
Table 40. Global Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 41. Global Pulmonary Fibrosis Drug Sales by Region (2024-2029) & (K Units)
Table 42. Global Pulmonary Fibrosis Drug Sales Market Share in Volume by Region (2024-2029)
Table 43. Global Pulmonary Fibrosis Drug Sales by Region (2024-2029) & (US$ Million)
Table 44. Global Pulmonary Fibrosis Drug Sales Market Share in Value by Region (2024-2029)
Table 45. Global Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2029)
Table 46. Global Pulmonary Fibrosis Drug Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 47. Global Pulmonary Fibrosis Drug Sales by Application (2018-2024) & (K Units)
Table 48. Global Pulmonary Fibrosis Drug Sales Market Share in Volume by Application (2018-2024)
Table 49. Global Pulmonary Fibrosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 50. Global Pulmonary Fibrosis Drug Sales Market Share in Value by Application (2018-2024)
Table 51. Global Pulmonary Fibrosis Drug Price by Application (2018-2024) & (US$/Unit)
Table 52. Global Pulmonary Fibrosis Drug Sales by Application (2024-2029) & (K Units)
Table 53. Global Pulmonary Fibrosis Drug Sales Market Share in Volume by Application (2024-2029)
Table 54. Global Pulmonary Fibrosis Drug Sales by Application (2024-2029) & (US$ Million)
Table 55. Global Pulmonary Fibrosis Drug Sales Market Share in Value by Application (2024-2029)
Table 56. Global Pulmonary Fibrosis Drug Price by Application (2024-2029) & (US$/Unit)
Table 57. North America Pulmonary Fibrosis Drug Sales by Application (2018-2024) (K Units)
Table 58. North America Pulmonary Fibrosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 59. Europe Pulmonary Fibrosis Drug Sales by Application (2018-2024) (K Units)
Table 60. Europe Pulmonary Fibrosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 61. Asia-Pacific Pulmonary Fibrosis Drug Sales by Application (2018-2024) (K Units)
Table 62. Asia-Pacific Pulmonary Fibrosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 63. Latin America Pulmonary Fibrosis Drug Sales by Application (2018-2024) (K Units)
Table 64. Latin America Pulmonary Fibrosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 65. Middle East and Africa Pulmonary Fibrosis Drug Sales by Application (2018-2024) (K Units)
Table 66. Middle East and Africa Pulmonary Fibrosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 67. North America Pulmonary Fibrosis Drug Sales by Country (2018-2024) & (K Units)
Table 68. North America Pulmonary Fibrosis Drug Sales Market Share in Volume by Country (2018-2024)
Table 69. North America Pulmonary Fibrosis Drug Sales by Country (2018-2024) & (US$ Million)
Table 70. North America Pulmonary Fibrosis Drug Sales Market Share in Value by Country (2018-2024)
Table 71. North America Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (K Units)
Table 72. North America Pulmonary Fibrosis Drug Sales Market Share in Volume by Country (2024-2029)
Table 73. North America Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (US$ Million)
Table 74. North America Pulmonary Fibrosis Drug Sales Market Share in Value by Country (2024-2029)
Table 75. Europe Pulmonary Fibrosis Drug Sales by Country (2018-2024) & (K Units)
Table 76. Europe Pulmonary Fibrosis Drug Sales Market Share in Volume by Country (2018-2024)
Table 77. Europe Pulmonary Fibrosis Drug Sales by Country (2018-2024) & (US$ Million)
Table 78. Europe Pulmonary Fibrosis Drug Sales Market Share in Value by Country (2018-2024)
Table 79. Europe Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (K Units)
Table 80. Europe Pulmonary Fibrosis Drug Sales Market Share in Volume by Country (2024-2029)
Table 81. Europe Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (US$ Million)
Table 82. Europe Pulmonary Fibrosis Drug Sales Market Share in Value by Country (2024-2029)
Table 83. Asia-Pacific Pulmonary Fibrosis Drug Sales by Region (2018-2024) & (K Units)
Table 84. Asia-Pacific Pulmonary Fibrosis Drug Sales Market Share in Volume by Region (2018-2024)
Table 85. Asia-Pacific Pulmonary Fibrosis Drug Sales by Region (2018-2024) & (US$ Million)
Table 86. Asia-Pacific Pulmonary Fibrosis Drug Sales Market Share in Value by Region (2018-2024)
Table 87. Asia-Pacific Pulmonary Fibrosis Drug Sales by Region (2024-2029) & (K Units)
Table 88. Asia-Pacific Pulmonary Fibrosis Drug Sales Market Share in Volume by Region (2024-2029)
Table 89. Asia-Pacific Pulmonary Fibrosis Drug Sales by Region (2024-2029) & (US$ Million)
Table 90. Asia-Pacific Pulmonary Fibrosis Drug Sales Market Share in Value by Region (2024-2029)
Table 91. Latin America Pulmonary Fibrosis Drug Sales by Country (2018-2024) & (K Units)
Table 92. Latin America Pulmonary Fibrosis Drug Sales Market Share in Volume by Country (2018-2024)
Table 93. Latin America Pulmonary Fibrosis Drug Sales by Country (2018-2024) & (US$ Million)
Table 94. Latin America Pulmonary Fibrosis Drug Sales Market Share in Value by Country (2018-2024)
Table 95. Latin America Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (K Units)
Table 96. Latin America Pulmonary Fibrosis Drug Sales Market Share in Volume by Country (2024-2029)
Table 97. Latin America Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (US$ Million)
Table 98. Latin America Pulmonary Fibrosis Drug Sales Market Share in Value by Country (2024-2029)
Table 99. Middle East and Africa Pulmonary Fibrosis Drug Sales by Country (2018-2024) & (K Units)
Table 100. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share in Volume by Country (2018-2024)
Table 101. Middle East and Africa Pulmonary Fibrosis Drug Sales by Country (2018-2024) & (US$ Million)
Table 102. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share in Value by Country (2018-2024)
Table 103. Middle East and Africa Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (K Units)
Table 104. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share in Volume by Country (2024-2029)
Table 105. Middle East and Africa Pulmonary Fibrosis Drug Sales by Country (2024-2029) & (US$ Million)
Table 106. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share in Value by Country (2024-2029)
Table 107. Boehringer Ingelheim Company Information
Table 108. Boehringer Ingelheim Introduction and Business Overview
Table 109. Boehringer Ingelheim Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Boehringer Ingelheim Pulmonary Fibrosis Drug Product
Table 111. Boehringer Ingelheim Recent Development
Table 112. Roche Company Information
Table 113. Roche Introduction and Business Overview
Table 114. Roche Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. Roche Pulmonary Fibrosis Drug Product
Table 116. Roche Recent Development
Table 117. FibroGen, Inc. Company Information
Table 118. FibroGen, Inc. Introduction and Business Overview
Table 119. FibroGen, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. FibroGen, Inc. Pulmonary Fibrosis Drug Product
Table 121. FibroGen, Inc. Recent Development
Table 122. Merck & Co., Inc. Company Information
Table 123. Merck & Co., Inc. Introduction and Business Overview
Table 124. Merck & Co., Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Merck & Co., Inc. Pulmonary Fibrosis Drug Product
Table 126. Merck & Co., Inc. Recent Development
Table 127. Bristol-Myers Squibb Company Company Information
Table 128. Bristol-Myers Squibb Company Introduction and Business Overview
Table 129. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product
Table 131. Bristol-Myers Squibb Company Recent Development
Table 132. MediciNova, Inc. Company Information
Table 133. MediciNova, Inc. Introduction and Business Overview
Table 134. MediciNova, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. MediciNova, Inc. Pulmonary Fibrosis Drug Product
Table 136. MediciNova, Inc. Recent Development
Table 137. Genentech, Inc. Company Information
Table 138. Genentech, Inc. Introduction and Business Overview
Table 139. Genentech, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Genentech, Inc. Pulmonary Fibrosis Drug Product
Table 141. Genentech, Inc. Recent Development
Table 142. Cipla Inc. Company Information
Table 143. Cipla Inc. Introduction and Business Overview
Table 144. Cipla Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. Cipla Inc. Pulmonary Fibrosis Drug Product
Table 146. Cipla Inc. Recent Development
Table 147. Biogen Company Information
Table 148. Biogen Introduction and Business Overview
Table 149. Biogen Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. Biogen Pulmonary Fibrosis Drug Product
Table 151. Biogen Recent Development
Table 152. Galapagos NV Company Information
Table 153. Galapagos NV Introduction and Business Overview
Table 154. Galapagos NV Pulmonary Fibrosis Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. Galapagos NV Pulmonary Fibrosis Drug Product
Table 156. Galapagos NV Recent Development
Table 157. Key Raw Materials Lists
Table 158. Raw Materials Key Suppliers Lists
Table 159. Pulmonary Fibrosis Drug Market Trends
Table 160. Pulmonary Fibrosis Drug Market Drivers
Table 161. Pulmonary Fibrosis Drug Market Challenges
Table 162. Pulmonary Fibrosis Drug Market Restraints
Table 163. Pulmonary Fibrosis Drug Distributors List
Table 164. Pulmonary Fibrosis Drug Downstream Customers
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources
List of Figures
Figure 1. Pulmonary Fibrosis Drug Product Picture
Figure 2. Global Pulmonary Fibrosis Drug Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Pulmonary Fibrosis Drug Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Pulmonary Fibrosis Drug Sales Status and Outlook (2018-2029) & (K Units)
Figure 5. Product Picture of Pirfenidone
Figure 6. Global Pirfenidone Sales YoY Growth (2018-2029) & (K Units)
Figure 7. Product Picture of Nintedanib
Figure 8. Global Nintedanib Sales YoY Growth (2018-2029) & (K Units)
Figure 9. Global Pulmonary Fibrosis Drug Sales by Type (2018-2029) & (US$ Million)
Figure 10. Global Pulmonary Fibrosis Drug Sales Market Share by Type in 2022 & 2029
Figure 11. North America Pulmonary Fibrosis Drug Sales Market Share in Volume by Type in 2022
Figure 12. North America Pulmonary Fibrosis Drug Sales Market Share in Value by Type in 2022
Figure 13. Europe Pulmonary Fibrosis Drug Sales Market Share in Volume by Type in 2022
Figure 14. Europe Pulmonary Fibrosis Drug Sales Market Share in Value by Type in 2022
Figure 15. Asia-Pacific Pulmonary Fibrosis Drug Sales Market Share in Volume by Type in 2022
Figure 16. Asia-Pacific Pulmonary Fibrosis Drug Sales Market Share in Value by Type in 2022
Figure 17. Latin America Pulmonary Fibrosis Drug Sales Market Share in Volume by Type in 2022
Figure 18. Latin America Pulmonary Fibrosis Drug Sales Market Share in Value by Type in 2022
Figure 19. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share in Volume by Type in 2022
Figure 20. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share in Value by Type in 2022
Figure 21. The 5 and 10 Largest Manufacturers in the World: Market Share by Pulmonary Fibrosis Drug Sales in 2022
Figure 22. The 5 and 10 Largest Manufacturers in the World: Market Share by Pulmonary Fibrosis Drug Revenue in 2022
Figure 23. Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 24. Product Picture of Hospital
Figure 25. Global Hospital Sales YoY Growth (2018-2029) & (K Units)
Figure 26. Product Picture of Clinic
Figure 27. Global Clinic Sales YoY Growth (2018-2029) & (K Units)
Figure 28. Global Pulmonary Fibrosis Drug Sales by Application (2018-2029) & (US$ Million)
Figure 29. Global Pulmonary Fibrosis Drug Sales Market Share by Application in 2022 & 2029
Figure 30. North America Pulmonary Fibrosis Drug Sales Market Share in Volume by Application in 2022
Figure 31. North America Pulmonary Fibrosis Drug Sales Market Share in Value by Application in 2022
Figure 32. Europe Pulmonary Fibrosis Drug Sales Market Share in Volume by Application in 2022
Figure 33. Europe Pulmonary Fibrosis Drug Sales Market Share in Value by Application in 2022
Figure 34. Asia-Pacific Pulmonary Fibrosis Drug Sales Market Share in Volume by Application in 2022
Figure 35. Asia-Pacific Pulmonary Fibrosis Drug Sales Market Share in Value by Application in 2022
Figure 36. Latin America Pulmonary Fibrosis Drug Sales Market Share in Volume by Application in 2022
Figure 37. Latin America Pulmonary Fibrosis Drug Sales Market Share in Value by Application in 2022
Figure 38. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share in Value by Application in 2022
Figure 39. Key Raw Materials Price
Figure 40. Pulmonary Fibrosis Drug Manufacturing Cost Structure
Figure 41. Pulmonary Fibrosis Drug Industrial Chain Analysis
Figure 42. Channels of Distribution
Figure 43. Distributors Profiles
Figure 44. Bottom-up and Top-down Approaches for This Report
Figure 45. Data Triangulation
Figure 46. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries